Sonnet BioTherapeutics Holdings, Inc., a biotechnology company based in Princeton, New Jersey, operates in the clinical stage with a primary focus on oncology. The firm is dedicated to developing novel platforms for creating biologic medicines that can exhibit either singular or dual therapeutic mechanisms. Central to their strategy is a proprietary fully human albumin binding technology. This innovative system employs human single-chain antibody fragments specifically engineered to bind to human serum albumin, leveraging it for enhanced delivery and transport to target tissues. Their leading therapeutic candidate, SON-1010, is a fully human variant of interleukin 12, currently being advanced for the treatment of non-small cell lung cancer and cancers affecting the head and neck. Additionally, Sonnet is progressing SON-080, another fully human interleukin 6 formulation, intended to address both chemotherapy-induced and diabetic peripheral neuropathy. The company also maintains a licensing agreement with New Life Therapeutics PTE, LTD., for the development and commercialization of pharmaceutical preparations containing a specific recombinant human interleukin 6.